5.46  0.04 (0.74%)		03-20 16:00
Open: 5.58 High: 5.67 Volume: 55,304		Pre. Close: 5.42 Low: 5.4 Market Cap: 385(M)

Short term
Mid term
Targets	6-month :	9.85	1-year :	12.04
Resists	First :	8.43	Second :	10.31
Pivot price	7.48
Supports	First :	5.4	Second :	4.49
MAs	MA(5) :	6.42	MA(20) :	7.72
	MA(100) :	10.68	MA(250) :	0
MACD	MACD :	-1.1	Signal :	-0.9
%K %D	K(14,3) :	2.2	D(3) :	4.5
RSI	RSI(14): 22.4
52-week	High :	25	Low :	5.3

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ YDES ] has closed below the lower bollinger band by 1.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ YDES ] is to continue within current trading range. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.67 - 5.71	5.71 - 5.74
Low:	5.32 - 5.36	5.36 - 5.4
Close:	5.4 - 5.46	5.46 - 5.51

Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.

Wed, 18 Mar 2026
YD Bio (YDES) CEO details direct and indirect share stakes - Stock Titan

Fri, 27 Feb 2026
YD Bio (NASDAQ: YDES) registers 11.5M warrant shares; announces Taiwan-U.S. FDA alliance - Stock Titan

Wed, 24 Dec 2025
YD Bio (YDES) Stock Price, News & Analysis - MarketBeat

Mon, 01 Sep 2025
YD Bio Limited Announces Closing of Business Combination - citybiz

Fri, 29 Aug 2025
YD Bio Limited Ordinary Shares (YDES) Stock Forecast & Price Prediction 2026–2030 - CoinCodex

Fri, 29 Aug 2025
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	71 (M)
Shares Float	0 (M)
Held by Insiders	81.3 (%)
Held by Institutions	0.4 (%)
Shares Short	44 (K)
Shares Short P.Month	47 (K)

EPS	-0.02
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.57
Profit Margin	-276.6 %
Operating Margin	-444.6 %
Return on Assets (ttm)	-25.5 %
Return on Equity (ttm)	-42.7 %
Qtrly Rev. Growth	95.5 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.02
Qtrly Earnings Growth	0 %
Operating Cash Flow	-2 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-273
PEG Ratio	0
Price to Book value	1.19
Price to Sales	754.44
Price to Cash Flow	-209.27

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.